Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

Drug Metabolism and Disposition : the Biological Fate of Chemicals
A David Rodrigues


The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance, in subjects expressing variant forms of the enzyme (e.g., CYP2C9*1/*3 or CYP2C9*3/*3 genotype), will lead to increased exposure and a greater risk of cardiovascular or gastrointestinal side effects. For any drug, however, one has to consider all clearance pathways. Therefore, a number of COX inhibitors were surveyed and it was determined that CYP2C9 plays a relatively minor role in the overall clearance (<or=20% of the dose) of sulindac, naproxen, ketoprofen, diclofenac, rofecoxib, and etoricoxib. CYP2C9 genotype would have no clinically meaningful impact on the pharmacokinetics of these drugs. In contrast, CYP2C9 genotype is expected to impact the clearance of ibuprofen, indomethacin, flurbiprofen, celecoxib, valdecoxib, lornoxicam, teno...Continue Reading


Nov 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P C RisdallB Marchant
Sep 1, 1990·Clinical Pharmacokinetics·F Jamali, D R Brocks
Jan 1, 1989·Drug Metabolism Reviews·T F Woolf, L L Radulovic
Jan 1, 1988·Journal of Pharmaceutical Sciences·R T FosterS R Alballa
Jan 1, 1987·European Journal of Clinical Pharmacology·C J RichardsonR K Verbeeck
May 1, 1987·Biopharmaceutics & Drug Disposition·G J SzpunarJ G Wagner
Jul 1, 1987·Clinical Pharmacology and Therapeutics·T P GibsonR O Davies
Jan 1, 1994·Clinical Pharmacokinetics·O G Nilsen
Feb 1, 1994·Clinical Pharmacokinetics·K T OlkkolaM J Mattila
Jan 1, 1996·European Journal of Clinical Pharmacology·S D FerraraP Palatini
Jan 1, 1997·European Journal of Clinical Pharmacology·T S TracyK R Korzekwa
Mar 11, 1998·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·C ChesnéT Sauter
Mar 27, 1998·Clinical Pharmacokinetics·N M Davies
Jul 1, 1998·Clinical Pharmacokinetics·N M Skjodt, N M Davies
Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Dec 5, 2000·Current Pharmaceutical Design·P McGettigan, D Henry
Jun 26, 2001·British Journal of Clinical Pharmacology·J H MartinM L Barclay
Jul 18, 2001·Biological & Pharmaceutical Bulletin·S KitamuraS Ohta
Mar 20, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Timothy S TracyLeslie J Dickmann
May 23, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rita A HalpinThomas A Baillie
Jun 27, 2002·Current Drug Metabolism·A David Rodrigues, Thomas H Rushmore
Aug 9, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Josh J YuanJohn W A Findlay
Oct 24, 2002·British Journal of Clinical Pharmacology·Mia SandbergErik Eliasson
Oct 31, 2002·Advanced Drug Delivery Reviews·Hong-Guang XieC Michael Stein
Nov 19, 2002·Biochemical and Biophysical Research Communications·Umit YasarAnders Rane
Jan 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·A David RodriguesNancy G B Agrawal
Jan 22, 2003·British Journal of Clinical Pharmacology·Julia KirchheinerJürgen Brockmöller
Jan 25, 2003·Clinical Pharmacology and Therapeutics·Marc K HalushkaPerry V Halushka
Feb 8, 2003·Current Atherosclerosis Reports·Richard J Bing

❮ Previous
Next ❯


Nov 14, 2007·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Mar 13, 2009·Archives of Pharmacal Research·Jung-Woo BaeSeok-Yong Lee
Apr 26, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Franciszek GłówkaWojciech Romanowski
Nov 13, 2013·Medicina clínica·Ana M Peiró Peiró
Oct 10, 2012·The Pharmacogenomics Journal·J E WyattS Harirforoosh
Aug 7, 2012·Journal of Veterinary Internal Medicine·G NobleS L Raidal
Aug 26, 2011·Science Translational Medicine·Mamoun M AlhamadshehIsabella A Graef
Jul 4, 2008·Pharmacogenomics·Victoria RollasonJules Desmeules
Sep 19, 2009·Pharmacogenomics·Elizabeth B Daily, Christina L Aquilante
May 28, 2010·Pharmacogenomics·Ulrike M StamerFrank Stüber
Aug 5, 2006·Pharmacogenomics·Federico Goodsaid, Felix Frueh
Oct 6, 2014·Seminars in Perinatology·Sara K QuinneyDavid A Flockhart
Feb 9, 2011·Bulletin of Environmental Contamination and Toxicology·C F GomezDuane B Huggett
Feb 27, 2008·The International Journal of Neuroscience·Naresh SharmaGiulio Maria Pasinetti
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Oct 6, 2007·Expert Opinion on Drug Metabolism & Toxicology·Hongjian ZhangA David Rodrigues
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·Emilio SternieriAnna Ferrari
Feb 13, 2016·Headache·Sylvia Lucas
Dec 31, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yueping ZhangDavid A Rodrigues
Jan 15, 2015·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Anita GuptaJohn Gallagher
Dec 10, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Susannah L CollinsMunir Pirmohamed
Aug 23, 2011·The Journal of Allergy and Clinical Immunology·Kenya KohyamaMotohiro Kurosawa
Jun 12, 2010·The American Journal of Cardiology·Christine G St GermaineJames M Brophy
Sep 16, 2010·British Journal of Clinical Pharmacology·Elina KumpulainenHannu Kokki
Jul 6, 2011·Basic & Clinical Pharmacology & Toxicology·Chang-Ik ChoiSeok-Yong Lee
Mar 5, 2016·Expert Opinion on Investigational Drugs·Nikolaos PapageorgiouDimitris Tousoulis
Jul 18, 2006·Pharmacology & Therapeutics·Mary Treinen-Moslen, Mary F Kanz
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Katerina AntoniouAlexandros A Drosos
Jan 7, 2015·Pharmacological Reports : PR·Annan Sudarsan Arun KumarChandrasekaran Adithan
Feb 12, 2017·The Journal of Nutritional Biochemistry·Viswanathan SaraswathiDahn L Clemens

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.